Compounds > pyridoxal phosphate

pyridoxal phosphate and clopidogrel

pyridoxal phosphate has been researched along with clopidogrel in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Graciano, ML; Jackson, K; Kobori, H; Navar, LG; Nishiyama, A; Ortiz, RM; Prieto-Carrasquero, MC; Seth, DM1
Hong, N; Kang, SM; Oh, J1

Other Studies

3 other study(ies) available for pyridoxal phosphate and clopidogrel

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension.
    American journal of physiology. Renal physiology, 2008, Volume: 294, Issue:1

    Topics: Actins; Adenosine Triphosphate; Angiotensin II; Animals; Arterioles; Blood Pressure; Cell Proliferation; Clopidogrel; Disease Models, Animal; Hypertension; Hypertrophy; Kidney; Male; Membrane Proteins; Mesangial Cells; Purinergic Antagonists; Purinergic P2 Receptor Antagonists; Pyridoxal Phosphate; Rats; Rats, Sprague-Dawley; Receptors, Purinergic; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Renin; Ticlopidine

2008
Clopidogrel treatment and the MEND-CABG II trial.
    JAMA, 2008, Sep-03, Volume: 300, Issue:9

    Topics: Clopidogrel; Coronary Artery Bypass; Humans; Myocardial Infarction; Myocardial Reperfusion Injury; Platelet Aggregation Inhibitors; Purinergic Antagonists; Pyridoxal Phosphate; Risk; Ticlopidine

2008